RXi Pharmaceuticals (RXII) Announces Initiation of First Clinical Trial
6/26/2012 11:08:31 AM
WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology. RXI-109 has been shown to effectively silence a key regulator of scarring, connective tissue growth factor (CTGF), in vitro in cell culture and in vivo in rodent skin models. After completion of the necessary toxicological studies and clearance of their IND submission by the US Food and Drug Administration, they have now successfully dosed their first subject in a dose escalation study.
comments powered by